Wei X. Guo
Expertise in
113
conditions

Wei X. Guo

Fuxing Road 28, 
Beijing, CN 
Expertise in
113
conditions
Fuxing Road 28, 
Beijing, CN 

Overview

Wei Guo practices in Beijing, China. Guo is highly rated in 113 conditions, according to our data. Their top areas of expertise are Bone Tumor, Osteosarcoma, Esophageal Cancer, Osteotomy, and Angioplasty.

Their clinical research consists of co-authoring 4280 peer reviewed articles and participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years.

Locations

Fuxing Road 28, Beijing, 100853, China
Other Locations
No. 61 Jiefang West Road, Changsha, 410005, China
Department Of Otorhinolaryngology Head And Neck Surgery, Beijing, China
180 Fenglin Road, Zhongshan, China
120 Dongling Road, Shenyang, 110866, China
No.157, Xi Wu Road, Xi'an, 710004, China
361 East Zhongshan Road, Shijiazhuang, 050017, China
241 Liuyang Road, Wuhan, 430063, China
Union Hospital, Wuhan, 430022, China
32 West Seventh Avenue, Tianjin, 300308, China
No.28 Fu Xing Road, Beijing, 100853, China
State Key Laboratory Of Robotics And System, Harbin, China
32 West 7Th Avenue, Tianjin, 300308, China
800 Xiangyin Rd, Yangpu, China
18 Chaowang Road, Hangzhou, 310014, China
197 Ruijin 2nd Road, Huangpu, 200025, China
Pokfulam Road, Hong Kong, China
238 Longyan Road, Guoyuan Xincun, 300134, China
No. 31, Huanghe West Road, Cangzhou, 061000, China
No. 157, Xi Wu Road, Xi'an, 710004, China
103 Wenhua Road, Shenyang, 110016, China
No. 71. Xinmin Street, Changchun, 130021, China
11 Xizhimen South Street, Xizhimen, China
No. 16 Airport Road, Guangzhou, 510405, China
5 Yushan Road, Qingdao, 266003, China
935 Jiao Ling Road, Kunming, 650118, China
No. 40 North Daxue Road, Zhengzhou, 450052, China
122 Luoshi Road, Wuhan, 430070, China
No. 399 Wanyuan Rd, Shanghai, 201102, China
300 Guangzhou Road, Nanjing, 210029, China
Changhai Road 399, Yangpu, 200438, China
#63 Nongye Road, Zhengzhou, 450002, China
No. 11 Xi Zhi Men South Street, Beijing, 100044, China
No. 11 Xi, Zhimen South Street, Beijing, 100044, China
State Key Laboratory Of Bioreactor Engineering, Shanghai, 200237, China
31 Huanghe Road, Cangzhou, 061001, China
No. 826, Zhangheng Road, Pudong, 201203, China
1095, Jiefang Avenue, Wuhan, 430030, China
No. 800 Xiangyin Road, Shanghai, 200433, China
Tianjin Key Laboratory For Industrial Biological Systems And Bioprocessing Engineering, Tianjin, 300308, China
58# Zhongshan 2rd Road, Guangzhou, 510080, China
7 Yanzishanxi Street, Jinan, 250014, China
No. 368, Hanjiang Road, Yangzhou, 225000, China
Xudong 2nd Road, Wuhan, 430062, China
5 South Zhongguancun Street, Haidian, 100081, China
Beinong Road 2, Beijing, 102206, China
No. 154 Anshan Road, Xiaobailou, 300052, China
No. 1200 Cailun Road, Shanghai, 201203, China
No. 103 Wenhua Road, Shenyang, 110016, China
127 West Youyi Rd, Xi'an, China
China Japan Union Hospital of Jilin University
Changchun, 130033, China
No.100 Kexue Road, Zhengzhou, 450001, China
225 Changhai Road, Shanghai, 200433, China
No. 639 Zhizaoju Rd, Shanghai, China
Jiankang Road 12, Shijiazhuang, China
No. 30, Fu Cheng Street, Haidian, 100142, China
127 Dongming Road, Zhengzhou, 450008, China
2-V Xinqiao Street, Xinqiao, 400037, China
325 Guohe Road, Shanghai, 200433, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

The Efficacy and Safety of TK216 in Subjects With Relapsed or Refractory Ewing's Sarcoma：a Phase II Clinical Trial in China
The Efficacy and Safety of TK216 in Subjects With Relapsed or Refractory Ewing's Sarcoma：a Phase II Clinical Trial in China
Enrollment Status: Completed
Publish Date: March 19, 2026
Intervention Type: Biological
Study Drug: TK216+Vincristin
Study Phase: Phase 2
Prospective Study for Aortic Arch Therapy With stENt-graft for Chimney technologY：A Prospective, Multi-center, Objective Performance Criteria Clinical Trial
Prospective Study for Aortic Arch Therapy With stENt-graft for Chimney technologY：A Prospective, Multi-center, Objective Performance Criteria Clinical Trial
Enrollment Status: Completed
Publish Date: June 18, 2025
Intervention Type: Device
Study Phase: Not Applicable
Guo's Visceral Arteries Reconstruction :The First in Man Study of G-Branch Multiple Branch Stent Graft System.
Guo's Visceral Arteries Reconstruction :The First in Man Study of G-Branch Multiple Branch Stent Graft System.
Enrollment Status: Completed
Publish Date: July 10, 2024
Intervention Type: Device
Study Phase: Not Applicable
Guo's Subclavian Artery Reconstruction: The Prospective, Multiple Center Study of WeFlow-Tbranch Stent Graft System(GUEST Study)
Guo's Subclavian Artery Reconstruction: The Prospective, Multiple Center Study of WeFlow-Tbranch Stent Graft System(GUEST Study)
Enrollment Status: Active_not_recruiting
Publish Date: April 30, 2024
Intervention Type: Device
Study Phase: Not Applicable
A Study to Assess the Therapeutic Efficacy in Advanced Osteosarcoma Patients In the Clinical Trial of SHR1020-SHR-1210-II-OS (Famitinib and Camrelizumab on Chemo-refractory Osteosarcoma) Based on Genomic Analyses of Tumor Specimens
A Study to Assess the Therapeutic Efficacy in Advanced Osteosarcoma Patients In the Clinical Trial of SHR1020-SHR-1210-II-OS (Famitinib and Camrelizumab on Chemo-refractory Osteosarcoma) Based on Genomic Analyses of Tumor Specimens
Enrollment Status: Completed
Publish Date: June 03, 2022
Intervention Type: Other
A Prospective, Multicenter, Single Arm Trial Evaluating the BARD Lutonix Drug-Coated Balloon (LTX DCB) for Treatment of Femoropopliteal Arteries (LEVANT China)
A Prospective, Multicenter, Single Arm Trial Evaluating the BARD Lutonix Drug-Coated Balloon (LTX DCB) for Treatment of Femoropopliteal Arteries (LEVANT China)
Enrollment Status: Completed
Publish Date: January 20, 2021
Intervention Type: Device
Study Phase: Not Applicable
Famitinib Malate (SHR1020) Plus Camrelizumab (SHR 1210) Versus Famitinib Malate Alone Versus Famitinib Malate Plus Ifosfamide Locally Advanced, Unresectable or Metastatic Osteosarcoma Progression Upon Chemotherapy: A Phase Ib/II Randomized and Controlled Dose-Escalation Trial
Famitinib Malate (SHR1020) Plus Camrelizumab (SHR 1210) Versus Famitinib Malate Alone Versus Famitinib Malate Plus Ifosfamide Locally Advanced, Unresectable or Metastatic Osteosarcoma Progression Upon Chemotherapy: A Phase Ib/II Randomized and Controlled Dose-Escalation Trial
Enrollment Status: Withdrawn
Publish Date: May 19, 2020
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
Apatinib Mesylate Plus Anti-PD1 Therapy (SHR-1210) in Locally Advanced, Unresectable or Metastatic Osteosarcoma(APFAO)Refractory to Chemotherapy : a Single Institution, Open-label, Phase 2 Trial
Apatinib Mesylate Plus Anti-PD1 Therapy (SHR-1210) in Locally Advanced, Unresectable or Metastatic Osteosarcoma(APFAO)Refractory to Chemotherapy : a Single Institution, Open-label, Phase 2 Trial
Enrollment Status: Completed
Publish Date: May 19, 2020
Intervention Type: Drug
Study Phase: Phase 2
Comparing the Effectiveness and Toxicity for Locally Advanced, Unresectable or Metastatic Soft-tissue Sarcoma Patients Who Had Received Total Dose of Anthracycline Antibiotics More Than 300mg/m2 With Pegylated Liposomal Doxorubicin Versus Pirarubicin Plus Ifosfamide, Dacarbazine, a Multicentre, Open-label, Randomised Phase 2 Trial
Comparing the Effectiveness and Toxicity for Locally Advanced, Unresectable or Metastatic Soft-tissue Sarcoma Patients Who Had Received Total Dose of Anthracycline Antibiotics More Than 300mg/m2 With Pegylated Liposomal Doxorubicin Versus Pirarubicin Plus Ifosfamide, Dacarbazine, a Multicentre, Open-label, Randomised Phase 2 Trial
Enrollment Status: Withdrawn
Publish Date: May 19, 2020
Intervention Type: Drug
Study Phase: Phase 2/Phase 3
View 8 Less Clinical Trials

4279 Total Publications

Few shots transfer learning for universal SPECT denoising across diverse acquisition protocols.
Few shots transfer learning for universal SPECT denoising across diverse acquisition protocols.
Journal: Physics in medicine and biology
Published: April 13, 2026

Frequently Asked Questions about Wei X. Guo

Is Wei X. Guo a top-rated expert for Bone Tumor?

MediFind is an objective health platform that identifies experts based on real-world data. Wei X. Guo is classified as an Elite expert for Bone Tumor, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Wei X. Guo participate in research or clinical trials?

Yes. Wei X. Guo has published 4279 articles and abstracts on conditions like Bone Tumor. You can view a list of Wei X. Guo's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Guo's expertise for a condition
ConditionClose
View All 25 Distinguished Conditions
View All 84 Advanced Conditions
View All 355 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile